Publications by authors named "R Versteeg"
Article Synopsis
- PFAS, particularly PFOS, pose environmental and health risks due to their long-lasting presence, making their fate and transport in sedimentary aquifers complex.
- The study examines how physical and geochemical differences in riparian floodplains affect the movement and concentration of PFOS during changes in river stages.
- Findings highlight that sediment permeability is crucial for predicting PFOS behavior, emphasizing the need to accurately assess aquifer variability to understand PFAS dynamics effectively.
Article Synopsis
- The researchers introduced a new resonant inelastic hard x-ray scattering setup at the Bernina beamline in SwissFEL, featuring high energy, momentum, and temporal resolution using a compact Johann-type spectrometer.
- They achieved an approximate resolution of 180 meV while studying honeycomb iridate α-LiIrO, confirming that their findings align well with previous synchrotron data.
- The time-resolved RIXS transients revealed energy loss changes less than 2 eV, linked to electron hopping in the lattice, which were attributed to modulation of inter-site transition scattering efficiency and transient changes in on-site Coulomb interaction.
Introduction: Cribriform growth pattern (CP) in prostate cancer (PCa) has been associated with different unfavourable oncological outcomes. This study addresses if CP in prostate biopsies is an independent risk factor for metastatic disease on PSMA PET/CT.
Methods: Treatment-naive patients with ISUP GG ≥ 2 staged with Ga-PSMA-11 PET/CT diagnosed from 2020 to 2021 were retrospectively enrolled.
Introduction: Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition . However, these inhibitors alone do not lead to tumor regression , indicating the need for combination therapy.
Methods And Results: high-throughput combination screening, we identified that the MEK inhibitor trametinib can be combined with BCL-2 family member inhibitors, to efficiently inhibit growth of neuroblastoma cell lines with RAS-MAPK mutations.